1
|
Lee YH, Cha HM, Hwang JY, Park SY, Vishakantegowda AG, Imran A, Lee JY, Yi YS, Jun S, Kim GH, Kang HJ, Chung SJ, Kim M, Kim H, Han SB. Sulfamoylbenzamide-based Capsid Assembly Modulators for Selective Inhibition of Hepatitis B Viral Replication. ACS Med Chem Lett 2021; 12:242-248. [PMID: 33603970 PMCID: PMC7883466 DOI: 10.1021/acsmedchemlett.0c00606] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2020] [Accepted: 12/29/2020] [Indexed: 02/08/2023] Open
Abstract
As the spread of infections caused by hepatitis B virus (HBV) threatens public health worldwide, investigations from multiple perspectives and of various mechanisms of action are urgently required to increase the HBV cure rate. Targeting the encapsidation of the nuclear capsid protein (core protein, HBc) has emerged as an attractive strategy for inhibiting the viral assembly process; however, a drug targeting this mechanism has not yet been approved. We synthesized novel sulfamoylbenzamides (SBAs) as capsid assembly modulators of HBV and found that the effects and safety profiles of compounds 3 and 8 have potential therapeutic applicability against HBV. The formation of tubular particles was time-dependent in the presence of 3, indicating a new mode of protein assembly by SBA compounds. Our findings provide a new entity for developing safe and efficient treatments for HBV infection.
Collapse
Affiliation(s)
- Yeon Hee Lee
- Therapeutics
& Biotechnology Division, Korea Research
Institute of Chemical Technology, Daejeon 34114, Republic of Korea
- Department
of Medicinal Chemistry and Pharmacology, University of Science & Technology, Daejeon 34113, Republic of Korea
| | - Hyeon-Min Cha
- Therapeutics
& Biotechnology Division, Korea Research
Institute of Chemical Technology, Daejeon 34114, Republic of Korea
- Graduate
School of New Drug Discovery and Development, Chungnam National University, Daejeon 34134, Republic
of Korea
| | - Jun Yeon Hwang
- Therapeutics
& Biotechnology Division, Korea Research
Institute of Chemical Technology, Daejeon 34114, Republic of Korea
| | - So Yeong Park
- Therapeutics
& Biotechnology Division, Korea Research
Institute of Chemical Technology, Daejeon 34114, Republic of Korea
- Department
of Medicinal Chemistry and Pharmacology, University of Science & Technology, Daejeon 34113, Republic of Korea
| | - Avinash G. Vishakantegowda
- Therapeutics
& Biotechnology Division, Korea Research
Institute of Chemical Technology, Daejeon 34114, Republic of Korea
- Department
of Medicinal Chemistry and Pharmacology, University of Science & Technology, Daejeon 34113, Republic of Korea
| | - Ali Imran
- Therapeutics
& Biotechnology Division, Korea Research
Institute of Chemical Technology, Daejeon 34114, Republic of Korea
| | - Joo-Youn Lee
- Therapeutics
& Biotechnology Division, Korea Research
Institute of Chemical Technology, Daejeon 34114, Republic of Korea
| | - Yoon-Sun Yi
- Center
for Research Equipment, Korea Basic Science
Institute, Cheongju 28119, Republic of Korea
| | - Sangmi Jun
- Center
for Research Equipment, Korea Basic Science
Institute, Cheongju 28119, Republic of Korea
| | - Ga Hyeon Kim
- School
of Pharmacy, Sungkyunkwan University, Suwon 16419, Republic of Korea
- AbTis Co.
Ltd. Suwon Venture Valley II, 142-10, Saneop-ro 156, Gwonseon-gu, Suwon 16648, Republic of Korea
| | - Hyo Jin Kang
- AbTis Co.
Ltd. Suwon Venture Valley II, 142-10, Saneop-ro 156, Gwonseon-gu, Suwon 16648, Republic of Korea
| | - Sang J. Chung
- School
of Pharmacy, Sungkyunkwan University, Suwon 16419, Republic of Korea
- AbTis Co.
Ltd. Suwon Venture Valley II, 142-10, Saneop-ro 156, Gwonseon-gu, Suwon 16648, Republic of Korea
| | - Meehyein Kim
- Therapeutics
& Biotechnology Division, Korea Research
Institute of Chemical Technology, Daejeon 34114, Republic of Korea
- Graduate
School of New Drug Discovery and Development, Chungnam National University, Daejeon 34134, Republic
of Korea
| | - Hyejin Kim
- Therapeutics
& Biotechnology Division, Korea Research
Institute of Chemical Technology, Daejeon 34114, Republic of Korea
| | - Soo Bong Han
- Therapeutics
& Biotechnology Division, Korea Research
Institute of Chemical Technology, Daejeon 34114, Republic of Korea
- Department
of Medicinal Chemistry and Pharmacology, University of Science & Technology, Daejeon 34113, Republic of Korea
| |
Collapse
|